NCT04907175
No Longer Available
Not Applicable
Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)
ConditionsSystem; Lupus Erythematosus
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- System; Lupus Erythematosus
- Sponsor
- Hope Biosciences Research Foundation
- Locations
- 1
- Status
- No Longer Available
- Last Updated
- 7 months ago
Overview
Brief Summary
This protocol is part of an FDA Individual Patient Expanded Access IND. This study is to be conducted according to US and International Standards of Good Clinical Practice (FDA Title 21 part 312 and International Conference on Harmonization guidelines), applicable government regulations and Hope Biosciences Stem Cell Research Foundation policies and procedures.
Detailed Description
This Individual Patient Expanded Access IND has been created per the request of a 65-year-old woman diagnosed with Systemic Lupus Erythematosus (SLE).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult individual 18 years of age or older.
- •Cognitively intact and capable of giving informed consent.
- •Clinical diagnosis of Systemic Lupus Erythematosus.
- •Subject has mesenchymal stem cells banked at Hope Biosciences.
- •The patient accepts to receive treatment and to comply with follow-up visits.
Exclusion Criteria
- •Clinically significant, uncontrolled cardiovascular, lung, renal, hepatic, or endocrine diseases that in the opinion of the investigator may increase the risks associated with study participation.
- •Active Alcohol or Drug addiction.
- •Participation in concurrent interventional research studies during this study.
- •Severe organ failure (heart, kidney or liver) confirmed by additional tests or medical history.
- •Unwillingness to return for follow-up visits.
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Individual Patient Expanded Access IND for the Treatment of StrokeStrokeStroke, IschemicNCT04907188Hope Biosciences Research Foundation
Unknown
Not Applicable
An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic Inflammatory Demyelinating PolyneuropathyNCT04825626Hope Biosciences Research Foundation
Unknown
Not Applicable
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCISpinal Cord Injury at C5-C7 LevelNCT03925649Hope Biosciences LLC
No Longer Available
Not Applicable
Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's DiseaseAlzheimer DiseaseNCT04855955Celltex Therapeutics Corporation
No Longer Available
Not Applicable
Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple MyelomaMultiple MyelomaNCT04452994Janssen Research & Development, LLC